BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18789923)

  • 1. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
    Kumar P; Sunkaraneni S; Sirohi S; Dighe SV; Walker EA; Yoburn BC
    Eur J Pharmacol; 2008 Nov; 597(1-3):39-45. PubMed ID: 18789923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
    Madia PA; Navani DM; Yoburn BC
    Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation.
    Sirohi S; Dighe SV; Walker EA; Yoburn BC
    Pharmacol Biochem Behav; 2008 Nov; 91(1):115-20. PubMed ID: 18640146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnitude of tolerance to fentanyl is independent of mu-opioid receptor density.
    Chan KW; Duttory A; Yoburn BC
    Eur J Pharmacol; 1997 Jan; 319(2-3):225-8. PubMed ID: 9042594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    Kögel B; Christoph T; Strassburger W; Friderichs E
    Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat.
    Tejwani GA; Rattan AK
    Anesth Analg; 2002 Jun; 94(6):1542-6, table of contents. PubMed ID: 12032023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
    Smith PA; Selley DE; Sim-Selley LJ; Welch SP
    Eur J Pharmacol; 2007 Oct; 571(2-3):129-37. PubMed ID: 17603035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
    Chan K; Brodsky M; Davis T; Franklin S; Inturrisi CE; Yoburn BC
    Eur J Pharmacol; 1995 Dec; 287(2):135-43. PubMed ID: 8749027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
    Matsumoto K; Takayama H; Narita M; Nakamura A; Suzuki M; Suzuki T; Murayama T; Wongseripipatana S; Misawa K; Kitajima M; Tashima K; Horie S
    Neuropharmacology; 2008 Aug; 55(2):154-65. PubMed ID: 18550129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
    Szentirmay AK; Király KP; Lenkey N; Lackó E; Al-Khrasani M; Friedmann T; Timár J; Gyarmati S; Tóth G; Fürst S; Riba P
    Brain Res Bull; 2013 Jan; 90():66-71. PubMed ID: 22995282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse.
    Madia PA; Dighe SV; Sirohi S; Walker EA; Yoburn BC
    Psychopharmacology (Berl); 2009 Dec; 207(3):413-22. PubMed ID: 19816677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
    Walker EA; Young AM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):101-10. PubMed ID: 12065706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new potent analgesic agent with reduced liability to produce morphine tolerance.
    Kiraly K; Caputi FF; Hanuska A; Kató E; Balogh M; Köles L; Palmisano M; Riba P; Hosztafi S; Romualdi P; Candeletti S; Ferdinandy P; Fürst S; Al-Khrasani M
    Brain Res Bull; 2015 Aug; 117():32-8. PubMed ID: 26235542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of morphine tolerance by processed Aconiti tuber is mediated by kappa-opioid receptors.
    Shu H; Arita H; Hayashida M; Chiba S; Sekiyama H; Hanaoka K
    J Ethnopharmacol; 2006 Jun; 106(2):263-71. PubMed ID: 16446067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at mu-opioid receptors.
    Wong CS; Cherng CH; Luk HN; Ho ST; Tung CS
    Eur J Pharmacol; 1996 Feb; 297(1-2):27-33. PubMed ID: 8851162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
    Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
    J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.